{"id":"W2595109760","doi":"10.1200/jco.2012.30.15_suppl.8035","title":"Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Bortezomib; Internal medicine; Clinical endpoint; Thalidomide; Lenalidomide; Gastroenterology; Multiple myeloma; Proteasome inhibitor; Progressive disease; Clinical trial; Phases of clinical research; Surgery; Oncology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164539,0.0003271402,0.0008262832,0.0002727027,0.0002147863,0.0004829528,0.0002706345,0.0005558375,0.002236534],"category_scores_gemma":[0.0008591835,0.0001501458,0.0007010848,0.0003028561,0.0002334562,0.000329554,0.0002325369,0.0007722648,0.0003491967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006155587,"about_ca_system_score_gemma":0.000446717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007217192,"about_ca_topic_score_gemma":0.0008423963,"domain_scores_codex":[0.9996736,0.0001076982,0.00002671765,0.0000806191,0.00003740523,0.00007401652],"domain_scores_gemma":[0.9991953,0.0001790403,0.0002172336,0.00004088544,0.00002712486,0.0003404306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6683138,0.006929026,0.1904668,0.0003950622,0.0009263895,0.000480135,0.0003225706,0.002414358,0.02526744,0.0001583034,0.003050521,0.1012756],"study_design_scores_gemma":[0.09008659,0.2488411,0.6409848,0.00005484494,0.001228069,0.001799061,0.000143925,0.003908725,0.007569706,0.000194913,0.005145783,0.00004246208],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981697,0.000735381,0.00006429804,0.00004992739,0.000008753154,0.00009481153,0.00042986,0.00001088142,0.0004363968],"genre_scores_gemma":[0.9983312,0.0001644446,0.00009282884,0.00007867574,0.00002241908,0.0001026295,0.0009052056,0.000004775397,0.000297896],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002236534,"threshold_uncertainty_score":0.007481992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1860781055459684,"score_gpt":0.5003545129570304,"score_spread":0.314276407411062,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}